Zacks Research Has Bullish Forecast for BMRN Q4 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Analysts at Zacks Research increased their Q4 2026 earnings per share estimates for BioMarin Pharmaceutical in a research report issued on Wednesday, July 16th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $1.20 for the quarter, up from their prior forecast of $1.18. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q1 2027 earnings at $1.30 EPS and FY2027 earnings at $5.31 EPS.

BMRN has been the topic of a number of other reports. Wall Street Zen lowered BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Friday. Morgan Stanley began coverage on BioMarin Pharmaceutical in a research report on Thursday, July 3rd. They set an "overweight" rating and a $97.00 target price for the company. JPMorgan Chase & Co. boosted their target price on BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. Citigroup reduced their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Finally, Wolfe Research set a $95.00 price objective on BioMarin Pharmaceutical and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.78.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN traded down $1.08 during mid-day trading on Friday, hitting $57.29. The stock had a trading volume of 1,740,774 shares, compared to its average volume of 1,756,379. The firm has a market cap of $10.99 billion, a P/E ratio of 21.30, a PEG ratio of 0.79 and a beta of 0.17. The business has a fifty day moving average price of $57.21 and a 200-day moving average price of $62.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.52 and a quick ratio of 3.49. BioMarin Pharmaceutical has a 52 week low of $52.93 and a 52 week high of $94.85.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently made changes to their positions in the business. Proficio Capital Partners LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter worth about $920,000. HighTower Advisors LLC lifted its stake in BioMarin Pharmaceutical by 34.9% in the 4th quarter. HighTower Advisors LLC now owns 41,468 shares of the biotechnology company's stock valued at $2,726,000 after buying an additional 10,730 shares in the last quarter. Avantax Advisory Services Inc. lifted its stake in BioMarin Pharmaceutical by 37.7% in the 4th quarter. Avantax Advisory Services Inc. now owns 5,950 shares of the biotechnology company's stock worth $391,000 after purchasing an additional 1,630 shares in the last quarter. Natixis Advisors LLC purchased a new position in BioMarin Pharmaceutical in the 4th quarter worth approximately $1,297,000. Finally, Signaturefd LLC increased its holdings in shares of BioMarin Pharmaceutical by 184.7% during the 4th quarter. Signaturefd LLC now owns 1,839 shares of the biotechnology company's stock worth $121,000 after buying an additional 1,193 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares in the company, valued at $840,600.63. This represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.